This research was supported by Brain and Behavior Foundation, NARSAD Young Investigator Award. Several 3D printed components were originally designed by Fabien Rabusseau (Image Guided Therapy, France). Author thanks John Heath (Caltech) and Margaret Swift (Caltech) for technical help with preparing the manuscript.

No conflict of interest.

ATAC requires successful implementation of several techniques for successful neuromodulation of specific neural circuits, including accurate MRI-guided targeting, FUS-BBBO, and histological evaluation of gene expression. 3D-printable components were developed to simplify targeting of small brain structures with imaging-guided FUS-BBBO.
MRI-guided focused ultrasound (MRIgFUS) administration poses a number of challenges. First, typical MRI coil has limited space that is designed to only accommodate a specimen and not the ultrasound hardware. The larger bores of MRIs increase the cost of equipment and decrease image quality, as the signal is related to the fill factor of a coil32. Consequently, any FUS hardware placed on the top of an animal image in MRI will compromise imaging quality. Second, designing MRI-compatible devices is difficult and expensive. MRI compatible materials need to be diamagnetic, have low propensity of creating eddy currents during radiofrequency irradiation, and have low magnetic susceptibility in high magnetic fields. In any conductive material, the creation of eddy currents or its magnetic susceptibility will also negatively affect imaging quality. Finally, the available MRI-compatible materials have lower Young&#8217;s moduli and durability than the metals typically used in production of precise targeting machines e.g., stereotaxic frames. The motors used for positional adjustments need to be MRI-compatible and placed outside of the MRI bore due to their size. These motors have to be connected at a distance to the transducer inside an MRI bore using MRI-compatible materials. Issues of plastic warping, lack of sufficient space inside the bore to implement robustly sized components, and insufficient room for changing targeting positions across the entire brain have affected targeting accuracy in previous work.
To resolve these problems, a decision was made to perform imaging in MRI and FUS-BBBO administration outside of the scanner. To allow for MRI-guidance, mice were placed inside a 3D-printed restraint that had an MRI-visible targeting guide that could be used to localize the mouse brain structures both in the MRI and in the stereotax coordinate space. Since both the mouse skull and the targeting guide are firmly attached to ear bar holders (Figure 1a,b), a targeting guide can be used to correlate spatial coordinates within MRI image and zero the stereotaxic instruments. The restraint does not have moving parts and does not contain a transducer, which allowed us to make it both robust and sufficiently small to fit inside an MRI and removed signal interference from transducer&#8217;s electronics. The space inside the targeting guide has been hollowed as the 3D-printed support for some materials is visible in MRI (Figure 1c). Holes in the assembly were introduced to enable stereotax calibration (Figure 3). The ultrasound transducer was attached to an electrode holder of a stereotax, and targeting was performed as described in section 4 (Figure 1d). The transducer should be supported along its length by housing of ear bars, preventing any deviation from the level plane. The targeting in the dorso-ventral direction can be achieved using phase-shifts in an annular array.
The practical targeting precision is determined by ultrasound focusing and skull attenuation. FUS-BBBO procedure has been described in detail for rats11 and has been implemented in a number of other model organisms23,33,34 and in humans16,17. The relationship between ultrasound focus size inversely proportional to frequency, where higher frequencies can result in more precise delivery. However, the attenuation of the skull increases with frequencies35 which may lead to skull heating and damage to the cortical areas. The exact targeting strategy will depend on the brain site. The sites where a full-width half maximum pressure fits within the brain tissue allow for predictable and safe BBB opening in many brain structures such as the striatum, midbrain, and hippocampus. Regions near the base of the brain pose a specific challenge in mice. Mouse brain measures approximately 8-10 mm in dorso-ventral direction, which is comparable to the full-width half maximum size of many commercially available transducers. Consequently, targeting at the bottom of the skull can lead to ultrasound reflection from the bones and air present in ear canals, mouth, or windpipe which can lead to unpredictable patterns of high and low pressures36. Some of these pressures can cross an inertial cavitation threshold which has been shown to cause bleeding and tissue damage37. To target regions which are located near the base of the skull, it may be preferable to use intersectional ATAC7, where intersectional genetics38 is used to restrict gene expression to a smaller area then the one targeted with FUS beam. In the published example of intersectional ATAC, a transgenic animal expressing a gene editing enzyme (Cre38) in dopaminergic cells has been targeted with ultrasound in the subsection of the region containing dopaminergic cells. Finally, the cortical regions can be targeted with FUS, but the diffraction and reflection of ultrasound may occur leading to uneven pressure profiles. This protocol does not cover the targeting of cortical regions as it will be highly dependent on the used species; however, some targeting of the cortex above hippocampus7 (e.g., Figure 7) has been observed indicating that at, least in mice, it is possible.
The choice of a chemogenetic activator and dosing will depend on the specific experimental needs. A number of studies, including one of the authors&#8217; studies7, showed no significant non-specific response39,40, while higher doses (e.g., 10 mg/kg) can produce side effects, at least in some cases41. However, as with all behavioral experiments, proper controls31 are essential due to potential off-targeted activity of CNO and its metabolites42. Such controls could include administration of CNO and saline controls to animals expressing DREADDs and administration of CNO to wild-type animals or in some specific cases a comparison of ipsi- and contralateral sites of the brain that respectively do and do not express chemogenetic receptors. Additionally, recent research revealed a number of new DREADD agonists with improved specificity28,29,43. Other chemogenetic receptors5,25,44 can also be used in conjunction with ATAC procedure.
Histological evaluation of gene expression is necessary post-mortem for every animal. A small fraction of animals show poor gene expression following FUS-BBBO7. Additionally, it is necessary to show the spatial accuracy and specificity of gene expression since mis-targeting is possible. Of note, some AAVs may show retrograde or anterograde tracing capability45 and can cause transfection far from the site targeted with ultrasound despite accurate ultrasound targeting. If the expressed chemogenetic receptor is fused to or co-expresses a fluorophore, imaging of the fluorophore in tissue sections may be sufficient to evaluate localization and intensity of expression. However, many fluorescent proteins are damaged by the tissue fixation process, and immunostaining for mCherry protein that is frequently used with DREADDs yielded better signal in previous studies7. Finally, due to the density of neurons in certain parts of the brain (e.g., granular cell layer in hippocampus), using nuclearly-localized fluorophores expressed under IRES, as opposed to fusions, to perform cell-counts may be beneficial since nuclei can be easily segmented and counterstained with nuclear stains, such as DAPI or TO-PRO-3. To evaluate neuromodulation by c-Fos staining, performing nuclear counterstaining and counting c-Fos positive nuclei, rather than any fluorescence signal, is imperative. In some cases, cellular debris can show fluorescence and confound the measurements of positive cells.
Limitations of the drug and gene delivery with FUS-BBBO include lower resolution than delivery with invasive intracranial injections and the need for larger amounts of injected drugs or viral vectors. Additionally, while a direct injection into the brain results in exclusive delivery to an injected site, FUS-BBBO uses an intravenous route resulting in possible delivery to peripheral tissues. Limitations of using chemogenetics for neuromodulation include a slow timescale, which may be inadequate to some behavioral protocols which require rapid changes in intensity of neuromodulation.

Use of circuit-specific neuromodulation technologies, such as optogenetics1,2 and chemogenetics3,4,5, has advanced our understanding of psychiatric conditions as neuronal-circuit disorders. Neuronal circuits are difficult to study and even more difficult to control in treating brain disorders because they are typically defined by specific cell types, brain regions, molecular signaling pathways and timing of activation. Ideally for both research and clinical applications, such control would be exerted noninvasively, but achieving both precise and noninvasive neuromodulation is challenging. For example, while neuroactive drugs can reach the brain noninvasively, they lack spatial specificity by acting throughout the brain. On the other hand, electrical deep-brain stimulation can control specific brain regions but has difficulty controlling specific cell types and requires surgery and device placement6.
Acoustically Targeted Chemogenetics7 (ATAC) provides neuromodulation with spatial, cell-type, and temporal specificity. It combines three techniques: focused ultrasound induced blood-brain barrier opening (FUS-BBBO) for spatial targeting, use of adeno-associated viral vectors (AAVs) to noninvasively deliver genes under the control of cell-type specific promoters, and engineered chemogenetic receptors to modulate transfected neural circuits selectively via drug administration. FUS is an FDA-approved technology that takes advantage of ultrasound&#8217;s ability to focus deep within tissues, including the human brain, with millimeter spatial precision. At high power, FUS is used for noninvasive targeted ablation, including an FDA-approved treatment for essential tremor8. FUS-BBBO combines low-intensity ultrasound with systemically administered microbubbles, which oscillate in blood vessels at the ultrasound focus, resulting in localized, temporary (6-24 h) and reversible opening of the BBB9. This opening allows for the delivery of proteins9,10, small molecules11, and viral vectors7,12,13,14 to the brain without significant tissue damage in rodents10 and non-human primates15. Clinical trials are ongoing for FUS-BBBO16,17, indicating possible therapeutic applications of this technique.
Viral gene delivery using AAV is also rapidly advancing into clinical use for CNS disorders, with recent FDA and EU regulatory approvals as major milestones. Finally, chemogenetic receptors18, such as Designer Receptors Activated Exclusively by Designer Drugs (DREADDs), are widely used by neuroscientists to provide pharmacological control over neuronal excitation in transgenic or transfected animals19,20. DREADDs are G protein-coupled receptors (GPCRs) that have been genetically engineered to respond to synthetic chemogenetic molecules rather than endogenous ligands, such that systemic administration of these ligands increases or reduces the excitability of DREADD-expressing neurons. When these three technologies are combined into ATAC, they can be used for the noninvasive modulation of selected neural circuits with spatial, cell-type, and temporal precision.
Here, we expand and update a previously published protocol for FUS-BBBO11 by including methodology for accurate targeting of brain regions with FUS-BBBO in mice using simple 3D printed targeting equipment. We, also, show an application of FUS-BBBO to ATAC. We show steps necessary for the delivery of AAVs carrying chemogenetic receptors, and evaluation of gene expression and neuromodulation by histology. This technique is particularly applicable for targeting large or multiple brain regions for gene expression or neuromodulation. For example, a wide area of a cortex can be easily transduced with FUS-BBBO and modulated using chemogenetics. However, gene delivery with an alternative technique, intracranial injections, would require large number of invasive injections and craniotomies. FUS-BBBO and its application, ATAC, can be scaled to animals of different sizes, where brain regions are larger and harder to target invasively.

<table border="0" cellpadding="0" cellspacing="0" style="width:875px;" width="873">
	<colgroup>
		<col />
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">21-gauge needles (BD)</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td style="width:161px;">14826C</td>
			<td style="width:275px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">25-gauge butterfly catheter</td>
			<td style="width:173px;">Harvard Bioscience</td>
			<td>725966</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">30-gauge needles (BD)</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td>14826F</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Absorbent blue pad</td>
			<td style="width:173px;">Office Depot</td>
			<td>902406</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Anti-c-Fos antibody</td>
			<td>Santa Cruz Biotechnology</td>
			<td style="width:161px;">SC-253-G</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Anti-mCherry antibody</td>
			<td style="width:173px;">Thermofisher</td>
			<td>PA534974</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Bruker Biospec 70/30</td>
			<td style="width:173px;">Bruker</td>
			<td style="width:161px;">custom</td>
			<td>includes the RF coils</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Clozapine-n-oxide</td>
			<td style="width:173px;">Tocris</td>
			<td style="width:161px;">4936</td>
			<td></td>
		</tr>
		<tr height="63">
			<td height="63" style="height:63px;width:265px;">Custom designed 3D printed mouse harnesses and MRIgFUS targeting components</td>
			<td style="width:173px;">ImageGuidedTherapy, Szablowski lab</td>
			<td style="width:161px;">custom</td>
			<td>download from szablowskilab.org/downloads</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Custom MRIgFUS machine</td>
			<td style="width:173px;">ImageGuidedTherapy</td>
			<td style="width:161px;">N/A</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Definity microbubbles</td>
			<td style="width:173px;">Lantheus</td>
			<td style="width:161px;">DE4</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Degassed aquasonic/ultrasound gel</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td>5067714</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Depilation cr&#232;me</td>
			<td style="width:173px;">Nair</td>
			<td style="width:161px;">n/a</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:265px;">Eight-element annular array transducer</td>
			<td style="width:173px;">Imasonic Inc.</td>
			<td style="width:161px;">custom</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:265px;">Ethanol Pads/Alcohol Swabs (70%) (BD)</td>
			<td style="width:173px;">Office Depot</td>
			<td>599893</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Heparin</td>
			<td style="width:173px;">Sigma-Aldrich</td>
			<td>H3149-25KU</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Isoflurane</td>
			<td style="width:173px;">Patterson Veterinary</td>
			<td style="width:161px;">07-893-1389</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Ketamine</td>
			<td style="width:173px;">Patterson Veterinary</td>
			<td style="width:161px;">07-890-8598</td>
			<td></td>
		</tr>
		<tr height="26">
			<td height="26" style="height:26px;width:265px;">Neutral buffered formalin (10%)</td>
			<td style="width:173px;">Sigma-Aldrich</td>
			<td>HT501128-4L</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Optical fiber hydrophone</td>
			<td style="width:173px;">Precision Acoustics</td>
			<td style="width:161px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">PE10 tubing</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td>NC1513314</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Peristaltic pump</td>
			<td style="width:173px;"></td>
			<td style="width:161px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Phosphate-buffered saline (PBS)</td>
			<td style="width:173px;">Sigma-Aldrich</td>
			<td>524650-1EA</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Prohance contrast agent</td>
			<td style="width:173px;">Bracco</td>
			<td>0270-1111-04</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Saline</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td style="width:161px;">NC9054335</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Secondary antibody, Donkey-anti goat</td>
			<td>ThermoFisher</td>
			<td style="width:161px;">A-11055</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:265px;">Secondary antibody, Donkey-anti rabbit</td>
			<td>ThermoFisher</td>
			<td style="width:161px;">84546</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Surgical scissors (straight)</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td>17467480</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">ThermoGuide Software</td>
			<td style="width:173px;">ImageGuidedTherapy</td>
			<td style="width:161px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Tissue glue (Gluture)</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td style="width:161px;">NC9855218</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Tuberculin Syringe (1 mL) (BD)</td>
			<td style="width:173px;">Fisher Scientific</td>
			<td>14823434</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">VeroClear 3D printable material</td>
			<td style="width:173px;">Stratasys</td>
			<td style="width:161px;">RGD810</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Vialmix microbubble activation device</td>
			<td style="width:173px;">Lantheus</td>
			<td style="width:161px;">VMIX</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Vibrating microtome</td>
			<td style="width:173px;">Compresstome</td>
			<td style="width:161px;">VF-300</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:265px;">Xylazine</td>
			<td style="width:173px;">Sigma-Aldrich</td>
			<td>X1251-1G</td>
			<td></td>
		</tr>
	</tbody>
</table>

focused ultrasound induced blood-brain barrier opening for targeting brain structures and evaluating chemogenetic neuromodulation

Acoustically Targeted Chemogenetics (ATAC) allows for the noninvasive control of specific neural circuits. ATAC achieves such control through a combination of focused ultrasound (FUS) induced blood-brain barrier opening (FUS-BBBO), gene delivery with adeno-associated viral (AAV) vectors, and activation of cellular signaling with engineered, chemogenetic, protein receptors and their cognate ligands. With ATAC, it is possible to transduce both large and small brain regions with millimeter precision using a single noninvasive ultrasound application. This transduction can later allow for a long-term, noninvasive, device-free neuromodulation in freely moving animals using a drug. Since FUS-BBBO, AAVs, and chemogenetics have been used in multiple animals, ATAC should also be scalable for the use in other animal species. This paper expands upon a previously published protocol and outlines how to optimize the gene delivery with FUS-BBBO to small brain regions with MRI-guidance but without a need for a complicated MRI-compatible FUS device. The protocol, also, describes the design of mouse targeting and restraint components that can be 3D-printed by any lab and can be easily modified for different species or custom equipment. To aid reproducibility, the protocol describes in detail how the microbubbles, AAVs, and venipuncture were used in ATAC development. Finally, an example data is shown to guide the preliminary investigations of studies utilizing ATAC.

The first step of performing ATAC protocol is the targeting of the FUS-BBBO to the desired brain regions. For example, following the described protocol, the hippocampus was targeted with FUS-BBBO, and contrast agent and AAV9 carrying DREADDs were injected into the mice, followed by a FLASH 3D MRI sequence that acquires images of the mouse brain. A T1 signal enhancement was achieved at the hippocampal region (Figure 6) and in other parts of the brain (Figure 7). After several weeks, DREADDs were expressed inside the target brain region. While many DREADDs are fused to a fluorescent reporter (e.g. mCherry), the process of perfusion and fixation with formaldehyde was found to drastically reduce the fluorescence of these proteins. Immunostaining against mCherry or the DREADD led to more reliable detection of the expression (Figure 8) based on previous experience. In previous experiments, ~85% of the mice showed expression following FUS-BBBO7. A simple test for sufficient levels of expression of DREADDs is testing their functionality on a cellular level. It can be done, for example, by providing a chemogenetic ligand or a saline control, such as CNO19, deschloroclozapine28, or others29, and waiting 2 hours before a cardiac perfusion and fixation. The brain sections were then co-immunostained for c-Fos protein30, which indicates heightened activity of neurons, and for DREADD. The experiment was considered successful, if the site of the brain targeted with DREADDs showed significantly higher number of neuronal nuclei that are c-Fos positive in the group that received a chemogenetic ligand when compared to the group that received saline7 or compared to a contralateral site that was not subjected to FUS-BBBO. Of note, there is a potential for some of these ligands to activate neurons non-specifically without expression of DREADDs. For example, CNO has been shown to be metabolized into low levels of clozapine in mice, which crosses the BBB and activates DREADDs with high potency27. However, it was also shown to bind to non-specific locations. As in every experiment, it is critical to include all proper controls in chemogenetic studies31. One possible control is administration of the chemogenetic ligand to wild-type mice, without procedures, to exclude effects of the drug alone on the desired behavioral or histological assay. Another control could be inclusion of four groups: DREADD + ligand, DREADD + vehicle, EGFP + ligand, EGFP + vehicle, which will account for any potential effects of both gene delivery with FUS-BBBO, and the chemogenetic ligand.
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/61352/61352fig1.jpg" /> 
Figure 1: The process of MRI-guided targeting of FUS in ATAC. (a) Mouse placement with ear bars, a nose cone and a platform that can be fit inside an MRI scanner. (b) A 3D-printed guide (blue) that is visible in MRI was attached to ends of ear bar frame and then secured in place with a holder of a surface MRI coil that contains four snap-on bolts (semi-transparent blue). (c) Appearance of the 3D-printed guide in sagittal MRI (left panel), with a bottom of the virtual representation of a transducer aligned (yellow semicircle) with the bottom of the guide. Right panel shows appearance of the 3D-printed guide on MRI from coronal view. The bright circle was made of a polyjet support material that has a strong MRI contrast. The cross was formed with plastic. A yellow circle represents transducer location which was aligned concentrically with the guide inside a stereotaxic frame. (d) To target brain structures a virtual transducer was moved in z-direction above the mice to match the thickness of an ultrasound cone / housing. In this case, because of the thickness of water bath, the transducer was moved 8.2 mm above the guide for accurate targeting. Brain structures were selected using MRI imaging data, and their MRI coordinates were then written down and entered into the stereotaxic machine. <a href="https://www.jove.com/files/ftp_upload/61352/61352fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/61352/61352fig2.jpg" /> 
Figure 2: Interface of the software used. <a href="https://www.jove.com/files/ftp_upload/61352/61352fig2large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/61352/61352fig3.jpg" /> 
Figure 3: Process of matching MRI coordinate space to stereotaxic instrument. (a) Three holes within a transducer holder were aligned with three holes within the MRI guide, and three conical targeting bolts were inserted without causing flex to the entire assembly. (b) Ideally, all three bolts would sit the center of the holes. (c) If there is any imprecision in alignment, not all three bolts would fit in e.g., in case of small, likely imperceptible yaw of 1&#176;, only one bolt would fit in while the opposite bolts would be stuck at the MRI guide. Alternatively, there could be visible flex of the entire assembly as bolts were forced through. (d) Enlarged view of bolt-fitting. The bolts should be placed concentrically for the best accuracy. <a href="https://www.jove.com/files/ftp_upload/61352/61352fig3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 4" class="xfigimg" src="/files/ftp_upload/61352/61352fig4.jpg" /> 
Figure 4: Rapid redistribution of microbubbles within the syringe. (a) Syringe was photographed 5 s after mixing. (b) One minute later, there was a clearly visible layer showing some of the bubbles concentrate near the top of 1 mL tuberculin syringe. This example, in particular, used a solution of microbubbles. <a href="https://www.jove.com/files/ftp_upload/61352/61352fig4large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 5" class="xfigimg" src="/files/ftp_upload/61352/61352fig5.jpg" /> 
Figure 5: Process of placing the center of a transducer over a center of an MRI guide. (a) In the models shown in this paper, the red carrier has been designed to move 10.56 mm forward from the position shown in Figure 3b, to one shown here. (b) The blue MRI guide was removed before sonication, and an ultrasound gel was applied between the mouse and the transducer (orange) to ensure ultrasound passage. <a href="https://www.jove.com/files/ftp_upload/61352/61352fig5large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 6" class="xfigimg" src="/files/ftp_upload/61352/61352fig6.jpg" /> 
Figure 6: MRI visualization of the BBB opening. (a) Axial view of the BBB opening. Brighter area designated with an arrowhead shows extravasation of an MRI T1 contrast agent. (b) Coronal view of the dorsal hippocampus and the cortex above hippocampus targeted with FUS-BBBO (arrowheads). (c) Coronal view of the central hippocampus targeted with FUS-BBBO (arrowheads). <a href="https://www.jove.com/files/ftp_upload/61352/61352fig6large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 7" class="xfigimg" src="/files/ftp_upload/61352/61352fig7.jpg" /> 
Figure 7: Example of targeting of 4 brain sites using the three-bolt targeting system described in this paper. Areas with arrowheads showed BBB opened sites with diffusion of an MRI contrast agent. The four sites were targeted in succession, with ~150 s between each BBB opening, from the bottom to top. The image was taken within 2 min after the last BBB opening. Scale bar is 2 mm. <a href="https://www.jove.com/files/ftp_upload/61352/61352fig7large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 8" class="xfigimg" src="/files/ftp_upload/61352/61352fig8.jpg" /> 
Figure 8: Detection of DREADD expression.&#160; (a) Immunostaining for the fluorophore attached to DREADDs, in this case mCherry was a reliable method of detection in some studies. (b) In another representative section with DREADDs targeted to hippocampus using the same conditions as in (a), the fluorescence of mCherry by itself produced strong background and relatively weak signal. (c) As a negative control, a mouse that received systemic injection of AAV, but did not undergo FUS-BBBO, was used. No significant expression can be found by mCherry immunostaining. Scale bars are 500 mm. (Data in a, c adapted from7 with permissions, Copyright 2020 Nature-Springer). <a href="https://www.jove.com/files/ftp_upload/61352/61352fig8large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

Watch this Scientific Journal Video about Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation at JoVE.com

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

This protocol delineates steps necessary for the gene delivery through focused ultrasound blood brain barrier (BBB) opening, evaluation of the resulting gene expression, and measurement of neuromodulation activity of chemogenetic receptors through histological tests.

Acoustically Targeted Chemogenetics (ATAC) allows for the noninvasive control of specific neural circuits. ATAC achieves such control through a ...

focused-ultrasound-induced-blood-brain-barrier-opening-for-targeting

Research

JoVE Journal

Neuroscience

3.4K Views.  Rice University. This protocol delineates steps necessary for the gene delivery through focused ultrasound blood brain barrier (BBB) opening, evaluation of the resulting gene expression, and measurement of neuromodulation activity of chemogenetic receptors through histological tests.

Video: Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Functional Neuroimaging Using Ultrasonic Blood-brain Barrier Disruption and Manganese-enhanced MRI

Although mice are the dominant model system for studying the genetic and molecular underpinnings of neuroscience, functional neuroimaging in mice remains technically challenging. One approach, Activation-Induced Manganese-enhanced MRI (AIM MRI), has been used successfully to map neuronal activity in rodents 1-5. In AIM MRI, Mn2+ acts a calcium analog and accumulates in depolarized neurons 6,7. Because Mn2+ shortens the T1 tissue property, regions of elevated neuronal activity will enhance in MRI. Furthermore, Mn2+ clears slowly from the activated regions; therefore, stimulation can be performed outside the magnet prior to imaging, enabling greater experimental flexibility. However, because Mn2+ does not readily cross the blood-brain barrier (BBB), the need to open the BBB has limited the use of AIM MRI, especially in mice.
One tool for opening the BBB is ultrasound. Though potentially damaging, if ultrasound is administered in combination with gas-filled microbubbles (i.e., ultrasound contrast agents), the acoustic pressure required for BBB opening is considerably lower. This combination of ultrasound and microbubbles can be used to reliably open the BBB without causing tissue damage 8-11.
Here, a method is presented for performing AIM MRI by using microbubbles and ultrasound to open the BBB. After an intravenous injection of perflutren microbubbles, an unfocused pulsed ultrasound beam is applied to the shaved mouse head for 3 minutes. For simplicity, we refer to this technique of BBB Opening with Microbubbles and UltraSound as BOMUS 12. Using BOMUS to open the BBB throughout both cerebral hemispheres, manganese is administered to the whole mouse brain. After experimental stimulation of the lightly sedated mice, AIM MRI is used to map the neuronal response.
To demonstrate this approach, herein BOMUS and AIM MRI are used to map unilateral mechanical stimulation of the vibrissae in lightly sedated mice 13. Because BOMUS can open the BBB throughout both hemispheres, the unstimulated side of the brain is used to control for nonspecific background stimulation. The resultant 3D activation map agrees well with published representations of the vibrissae regions of the barrel field cortex 14. The ultrasonic opening of the BBB is fast, noninvasive, and reversible; and thus this approach is suitable for high-throughput and/or longitudinal studies in awake mice.

A technique is described for broadly opening the blood-brain barrier in the mouse using microbubbles and ultrasound. Using this technique, manganese can be administered to the mouse brain. Because manganese is an MRI contrast agent that accumulates in depolarized neurons, this approach enables imaging of neuronal activity.

Although mice are the dominant model system for studying the genetic and molecular underpinnings of neuroscience, functional neuroimaging in mice remains ...

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease

Disruption of blood-brain barrier (BBB) integrity is a common feature for different neurological and neurodegenerative diseases. Although the interplay between perturbed BBB homeostasis and the pathogenesis of brain disorders needs further investigation, the development and validation of a reliable procedure to accurately detect BBB alterations may be crucial and represent a useful tool for potentially predicting disease progression and developing targeted therapeutic strategies.
Here, we present an easy and efficient procedure for evaluating BBB leakage in a neurodegenerative condition like that occurring in a preclinical mouse model of Huntington disease, in which defects in the permeability of BBB are clearly detectable precociously in the disease. Specifically, the high molecular weight fluorescein isothiocyanate labelled (FITC)-albumin, which is able to cross the BBB only when the latter is impaired, is acutely infused into a mouse jugular vein and its distribution in the vascular or parenchymal districts is then determined by fluorescence microscopy.
Accumulation of green fluorescent-albumin in the brain parenchyma functions as an index of aberrant BBB permeability and, when quantitated by using Image J processing software, is reported as Green Fluorescence Intensity.

In this study, we present an easy and efficient procedure for evaluating the disruption of the blood-brain barrier under neurodegenerative conditions. To achieve our objective, we infused high molecular weight fluorescein isothiocyanate labelled (FITC)-albumin into mouse jugular vein and evaluated its leakage into the brain parenchyma by fluorescence microscopy.

Disruption of blood-brain barrier (BBB) integrity is a common feature for different neurological and neurodegenerative diseases. Although the interplay ...

High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis

The blood-brain barrier (BBB) is a dynamic multicellular interface that regulates the transport of molecules between the circulation and the brain. Transcytosis across the BBB regulates the delivery of hormones, metabolites, and therapeutic antibodies to the brain parenchyma. Here, we present a protocol that combines immunofluorescence of free-floating sections with laser scanning confocal microscopy and image analysis to visualize subcellular organelles within endothelial cells at the BBB. Combining this data-set with 3D image analysis software allows for the semi-automated segmentation and quantification of capillary volume and surface area, as well as the number and intensity of intracellular organelles at the BBB. The detection of mouse endogenous immunoglobulin (IgG) within intracellular vesicles and their quantification at the BBB is used to illustrate the method. This protocol can potentially be applied to the investigation of the mechanisms controlling BBB transcytosis of different molecules in vivo.

Here we present a microscopy-based protocol for high-resolution imaging and a three-dimensional reconstruction of the mouse neurovascular unit and blood-brain barrier using brain free-floating sections. This method allows for the visualization, analysis, and quantification of intracellular organelles at the BBB.

The blood-brain barrier (BBB) is a dynamic multicellular interface that regulates the transport of molecules between the circulation and the brain. ...

An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers

Blood-brain barrier (BBB) is a specialized barrier that protects the brain microenvironment from toxins and pathogens in the circulation and maintains brain homeostasis. The principal sites of the barrier are endothelial cells of the brain capillaries whose barrier function results from tight intercellular junctions and efflux transporters expressed on the plasma membrane. This function is regulated by pericytes and astrocytes that together form the neurovascular unit (NVU). Several neurological diseases such as stroke, Alzheimer&#39;s disease (AD), brain tumors are associated with an impaired BBB function. Assessment of the BBB permeability is therefore crucial in evaluating the severity of the neurological disease and the success of the treatment strategies employed.
We present here a simple yet robust permeability assay that have been successfully applied to several mouse models both, genetic and experimental. The method is highly quantitative and objective in comparison to the tracer fluorescence analysis by microscopy that is commonly applied. In this method, mice are injected intraperitoneally with a mix of aqueous inert fluorescent tracers followed by anesthetizing the mice. Cardiac perfusion of the animals is performed prior to harvesting brain, kidneys or other organs. Organs are homogenized and centrifuged followed by fluorescence measurement from the supernatant. Blood drawn from the cardiac puncture just before perfusion serves for normalization purpose to the vascular compartment. The tissue fluorescence is normalized to the wet weight and serum fluorescence to obtain a quantitative tracer permeability index. For additional confirmation, the contralateral hemi-brain preserved for immunohistochemistry can be utilized for tracer fluorescence visualization purposes.

An In Vivo Blood-brain Barrier Permeability Assay in Mice Using Fluorescently Labeled Tracers

Here we present a mouse brain vascular permeability assay using intraperitoneal injection of fluorescent tracers followed by perfusion that is applicable to animal models of blood-brain barrier dysfunction. One hemi-brain is used for assessing permeability quantitatively and the other for tracer visualization/immunostaining. The procedure takes 5 - 6 h for 10 mice.

Blood-brain barrier (BBB) is a specialized barrier that protects the brain microenvironment from toxins and pathogens in the circulation and maintains ...

An In Vivo Assessment of Blood-Brain Barrier Disruption in a Rat Model of Ischemic Stroke

Ischemic stroke leads to vasogenic cerebral edema and subsequent primary brain injury, which is mediated through destruction of the blood-brain barrier (BBB). Rats with induced ischemic stroke were established and used as in vivo models to investigate the functional integrity of the BBB. Spectrophotometric detection of Evans blue (EB) in the brain samples with ischemic injury could provide reliable justification for the research and development of novel therapeutic modalities. This method generates reproducible results, and is applicable in any laboratory without a need for special equipment. Here, we present a visualized and technical guideline on the detection of the extravasation of EB following induction of ischemic stroke in rats.

An In Vivo Assessment of Blood-Brain Barrier Disruption in a Rat Model of Ischemic Stroke

The overall goal of this procedure is to provide a highly reproducible technique for in vivo assessment of the blood-brain barrier disruption in rat models of ischemic stroke.

Ischemic stroke leads to vasogenic cerebral edema and subsequent primary brain injury, which is mediated through destruction of the blood-brain barrier ...

A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model

Stereotaxic surgery is the gold standard for localized drug and gene delivery to the rodent brain. This technique has many advantages over systemic delivery including precise localization to a target brain region and reduction of off target side effects. However, stereotaxic surgery is highly invasive which limits its translational efficacy, requires long recovery times, and provides challenges when targeting multiple brain regions. Focused ultrasound (FUS) can be used in combination with circulating microbubbles to transiently open the blood brain barrier (BBB) in millimeter sized regions. This allows intracranial localization of systemically delivered agents that cannot normally cross the BBB. This technique provides a noninvasive alternative to stereotaxic surgery. However, to date this technique has yet to be widely adopted in neuroscience laboratories due to the limited access to equipment and standardized methods. The overall goal of this protocol is to provide a benchtop approach to FUS BBB opening (BBBO) that is affordable and reproducible and can therefore be easily adopted by any laboratory.

Focused ultrasound with microbubble agents can open the blood brain barrier focally and transiently. This technique has been used to deliver a wide range of agents across the blood brain barrier. This article provides a detailed protocol for the localized delivery to the rodent brain with or without MRI guidance.

Stereotaxic surgery is the gold standard for localized drug and gene delivery to the rodent brain. This technique has many advantages over systemic ...

A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents

The blood-brain barrier (BBB) has been a major hurdle for the treatment of various brain diseases. Endothelial cells, connected by tight junctions, form a physiological barrier preventing large molecules (&#62;500 Da) from entering the brain tissue. Microbubble-mediated focused ultrasound (FUS) can be used to induce a transient local BBB opening, allowing larger drugs to enter the brain parenchyma.
In addition to large-scale clinical devices for clinical translation, preclinical research for therapy response assessment of drug candidates requires dedicated small animal ultrasound setups for targeted BBB opening. Preferably, these systems allow high-throughput workflows with both high-spatial precision as well as integrated cavitation monitoring, while still being cost effective in both initial investment and running costs.
Here, we present a bioluminescence and X-ray guided stereotactic small animal FUS system that is based on commercially available components and fulfills the aforementioned requirements. A particular emphasis has been placed on a high degree of automation facilitating the challenges typically encountered in high-volume preclinical drug evaluation studies. Examples of these challenges are the need for standardization in order to ensure data reproducibility, reduce intra-group variability, reduce sample size and thus comply with ethical requirements and decrease unnecessary workload. The proposed BBB system has been validated in the scope of BBB opening facilitated drug delivery trials on patient-derived xenograft models of glioblastoma multiforme and diffuse midline glioma.

The blood-brain barrier (BBB) can be temporarily disrupted with microbubble-mediated focused ultrasound (FUS). Here, we describe a step-by-step protocol for high-throughput BBB opening in vivo using a modular FUS system accessible for non-ultrasound experts.

The blood-brain barrier (BBB) has been a major hurdle for the treatment of various brain diseases. Endothelial cells, connected by tight junctions, form a ...

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Surgical intervention can be quite effective for treating certain types of medically intractable neurological diseases. This approach is particularly useful for disorders in which identifiable neuronal circuitry plays a key role, such as epilepsy and movement disorders. Currently available surgical modalities, while effective, generally involve an invasive surgical procedure, which can result in surgical injury to non-target tissues. Consequently, it would be of value to expand the range of surgical approaches to include a technique that is both non-invasive and neurotoxic.
Here, a method is presented for producing focal, neuronal lesions in the brain in a non-invasive manner. This approach utilizes low-intensity focused ultrasound together with intravenous microbubbles to transiently and focally open the Blood Brain Barrier (BBB). The period of transient BBB opening is then exploited to focally deliver a systemically administered neurotoxin to a targeted brain area. The neurotoxin quinolinic acid (QA) is normally BBB-impermeable, and is well-tolerated when administered intraperitoneally or intravenously. However, when QA gains direct access to brain tissue, it is toxic to the neurons. This method has been used in rats and mice to target specific brain regions. Immediately after MRgFUS, successful opening of the BBB is confirmed using contrast enhanced T1-weighted imaging. After the procedure, T2 imaging shows injury restricted to the targeted area of the brain and the loss of neurons in the targeted area can be confirmed post-mortem utilizing histological techniques. Notably, animals injected with saline rather than QA do demonstrate opening of the BBB, but dot not exhibit injury or neuronal loss. This method, termed Precise Intracerebral Non-invasive Guided surgery (PING) could provide a non-invasive approach for treating neurological disorders associated with disturbances in neural circuitry.

The goal of the protocol is to provide a method for producing non-invasive neuronal lesions in the brain. The method utilizes Magnetic Resonance-guided Focused Ultrasound (MRgFUS) to open the Blood Brain Barrier in a transient and focal manner, in order to deliver a circulating neurotoxin to the brain parenchyma.

Surgical intervention can be quite effective for treating certain types of medically intractable neurological diseases. This approach is particularly ...

Measuring Post-Stroke Cerebral Edema, Infarct Zone and Blood-Brain Barrier Breakdown in a Single Set of Rodent Brain Samples

One of the most common causes of morbidity and mortality worldwide is ischemic stroke. Historically, an animal model used to stimulate ischemic stroke involves middle cerebral artery occlusion (MCAO). Infarct zone, brain edema and blood-brain barrier (BBB) breakdown are measured as parameters that reflect the extent of brain injury after MCAO. A significant limitation to this method is that these measurements are normally obtained in different rat brain samples, leading to ethical and financial burdens due to the large number of rats that need to be euthanized for an appropriate sample size. Here we present a method to accurately assess brain injury following MCAO by measuring infarct zone, brain edema and BBB permeability in the same set of rat brains. This novel technique provides a more efficient way to evaluate the pathophysiology of stroke.

This protocol describes a novel technique of measuring the three most important parameters of ischemic brain injury on the same set of rodent brain samples. Using only one brain sample is highly advantageous in terms of ethical and economic costs.

One of the most common causes of morbidity and mortality worldwide is ischemic stroke. Historically, an animal model used to stimulate ischemic stroke ...

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound

Only a small fraction of therapeutic antibodies targeting brain diseases are taken up by the brain. Focused ultrasound offers a possibility to increase uptake of antibodies and engagement through transient opening of the blood-brain barrier (BBB). In our laboratory, we are developing therapeutic approaches for neurodegenerative diseases in which an antibody in various formats is delivered across the BBB using microbubbles, concomitant with focused ultrasound application through the skull targeting multiple spots, an approach we refer to as scanning ultrasound (SUS). The mechanical effects of microbubbles and ultrasound on blood vessels increases paracellular transport across the BBB by transiently separating tight junctions and enhances vesicle- mediated transcytosis, allowing antibodies and therapeutic agents to effectively cross. Moreover, ultrasound also facilitates the uptake of antibodies from the interstitial brain into brain cells such as neurons where the antibody distributes throughout the cell body and even into neuritic processes. In our studies, fluorescently labeled antibodies are prepared, mixed with in-house prepared lipid-based microbubbles and injected into mice immediately before SUS is applied to the brain. The increased antibody concentration in the brain is then quantified. To account for alterations in normal brain homeostasis, microglial phagocytosis can be used as a cellular marker. The generated data suggest that ultrasound delivery of antibodies is an attractive approach to treat neurodegenerative diseases.

Presented here is a protocol to transiently open the blood-brain barrier (BBB) either focally or throughout a mouse brain to deliver fluorescently-labeled antibodies and activate microglia. Also presented is a method to detect the delivery of antibodies and microglia activation by histology.

Only a small fraction of therapeutic antibodies targeting brain diseases are taken up by the brain. Focused ultrasound offers a possibility to increase ...